# HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011

Source: https://nuclide.cc/trials/nct06369831/  
Nuclide record `nct06369831` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of an investigational treatment in advanced solid tumours, run by Abscint NV/SA, now recruiting.

## Summary

HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011 is a phase 2 interventional study registered as NCT06369831 by Abscint NV/SA, with 60 participants planned, started 2024-09-12 and due to reach its primary completion in 2026-09.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: HERMIA
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06369831
- Phase: 2
- Setting: Evaluating the Diagnostic Performance of Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Positron Emission Tomography and Computed Tomography (PET/CT) With 68Ga-ABS011 in Metastatic Breast Cancer (mBC) and Other Metastatic Solid Carcinomas.
- Sponsor: Abscint NV/SA
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06369831: https://clinicaltrials.gov/study/NCT06369831

## Connected records

- isotopes: [Gallium-68](https://nuclide.cc/isotopes/ga-68/)
- technologies: [PET (positron emission tomography)](https://nuclide.cc/technologies/pet/), [PET/CT](https://nuclide.cc/technologies/pet-ct/)
- targets: [HER2](https://nuclide.cc/targets/her2/)

---
JSON: https://nuclide.cc/api/v1/entities/nct06369831.json